- Summit NJ, US John R. Coombs - New Brunswick NJ, US Keming Zhu - New Brunswick NJ, US Daniel Lim - Summit NJ, US Candice Lee Joe - New Brunswick NJ, US David T. George - New Brunswick NJ, US Bin Zheng - Kendall Park NJ, US Dong Lin - Monmouth Junction NJ, US
International Classification:
C07D 495/14 C07C 255/50 C07D 215/58 C07D 495/04
Abstract:
The present disclosure provides novel synthetic intermediates useful in the synthesis of MK2 kinase inhibitors.
Process For The Preparation Of N-((1R,2S,5R)-5-(Tert-Butylamino)-2-((S)-3-(7-Tert-Butylpyrazolo[1,5-A][1,3,5]Triazin-4-Ylamino)-2-Oxopyrrolidin-1-Yl)Cyclohexyl)Acetamide
- Princeton NJ, US Collin Chan - New York NY, US Joerg Deerberg - Columbus NJ, US Nathan R. Domagalski - Niantic CT, US Martin D. Eastgate - Titusville NJ, US Yu Fan - Highland Park NJ, US Michael David Bengt Fenster - New York NY, US Robert V. Forest - Hillsborough NJ, US Rebecca A. Green - Metuchen NJ, US Matthew R. Hickey - Yardley PA, US Nathaniel David Kopp - Newtown PA, US Thomas E. La Cruz - Flemington NJ, US Kathleen Lauser - Minneapolis MN, US Hong Geun Lee - Seoul, KR David K. Leahy - Hightstown NJ, US Helen Y. Luo - San Francisco CA, US Thomas M. Razler - Yardley PA, US Scott A. Savage - Yardley PA, US Chris Sfouggatakis - Staten Island NY, US Maxime C.D. Soumeillant - Princeton NJ, US Serge Zaretsky - Fords NJ, US Bin Zheng - Kendall Park NJ, US Ye Zhu - Singapore, SG
International Classification:
C07D 487/04
Abstract:
The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide,
Process For The Preparation Of N-((1R,2S,5R)-5-(Tert-Butylamino)-2-((S)-3-(7-Tert-Butylpyrazolo[1,5-A][1,3,5]Triazin-4-Ylamino)-2-Oxopyrrolidin-1-Yl)Cyclohexyl)Acetamide
- Princeton NJ, US Collin Chan - New York NY, US Joerg Deerberg - Columbus NJ, US Nathan R. Domagalski - Niantic CT, US Martin D. Eastgate - Titusville NJ, US Yu Fan - Highland Park NJ, US Michael David Bengt Fenster - New York NY, US Robert V. Forest - Hillsborough NJ, US Rebecca A. Green - Metuchen NJ, US Matthew R. Hickey - Yardley PA, US Nathaniel David Kopp - Newtown PA, US Thomas E. La Cruz - Flemington NJ, US Kathleen Lauser - Minneapolis MN, US Hong Geun Lee - Seoul, KR David K. Leahy - Hightstown NJ, US Helen Y. Luo - San Francisco CA, US Thomas M. Razler - Yardley PA, US Scott A. Savage - Yardley PA, US Chris Sfouggatakis - Staten Island NY, US Maxime C.D. Soumeillant - Princeton NJ, US Serge Zaretsky - Fords NJ, US Bin Zheng - Kendall Park NJ, US Ye Zhu - Singapore, SG
International Classification:
C07D 487/04
Abstract:
The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolodin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
Process For The Preparation Of N,N-Dicyclopropyl-4-(1,5-Dimethyl-1H-Pyrazol-3-Ylamino)-6-Ethyl-1-Methyl-1,6-Dihydroimidazo[4,5-D]Pyrrolo[2,3-B]Pyridine-7-Carboxamide
- Princeton NJ, US Gregory L. Beutner - Green Brook NJ, US Benjamin Cohen - Cranford NJ, US Nicolas Cuniere - Belle Mead NJ, US Lopa V. Desai - Chesterfield NJ, US Monica Fitzgerald - Edison NJ, US Qi Gao - Franklin Park NJ, US Michael Bryan Hay - Scotch Plains NJ, US Michael Joseph Lawler - Mequon WI, US Paul C. Lobben - Lawrenceville NJ, US Christopher S. Regens - San Francisco CA, US Thorsten Rosner - Berkeley Heights NJ, US Neil Strotman - Somerset NJ, US Carolyn S. Wei - Hoboken NJ, US Yi Xiao - Fanwood NJ, US Bin Zheng - Kendall park NJ, US Keming Zhu - Highland Park NJ, US
International Classification:
C07D 471/14 C07D 403/04 C07D 231/16 C07D 207/42
Abstract:
The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.